 Challenges in Inflammatory Bowel Disease, 2nd Edition
ISBN: 978-1-4051-2234-4
Hardcover
416 pages
July 2006, Wiley-Blackwell
US $139.95
 Add to Cart
This price is valid for United States. Change location to view local pricing and availability. |
An online version of this product is available through our subscription-based content service. Visit Wiley InterScience now |
I Clues to aetiology and pathogenesis.
1 Global changes in incidence.
2 The role of genetics in inflammatory bowel disease.
3 Microbial sensing in the intestine by pattern recognition receptors.
4 The role of bacteria.
5 The appendix - how might it influence susceptibility to ulcerative.
colitis: the legend of Qebehsenuef.
II Diagnosis and assessment.
6 What are the controversies in histopathological diagnosis?.
7 The challenges of using capsule endoscopy in the diagnosis and management of inflammatory bowel disease.
8 Cross-sectional imaging of inflammatory bowel disease.
III Management of ulcerative colitis.
9 Mesalazine for maintenance therapy in ulcerative colitis - how much, how long?.
10 Refractory distal colitis.
11 Pharmabiotics and inflammatory bowel disease - on the verge of evidence-based medicine.
12 Current controversies in the surgical management of ulcerative colitis.
13 What are the causes and treatment of ileoanal pouch dysfunction?.
IV Management of Crohn's disease.
14 Is mesalazine useful in Crohn's disease?.
15 Steroids or nutrition?.
16 Do antibiotics have a role in Crohn's disease?.
17 The optimal use of infliximab in Crohn's disease.
18 Designer drugs: from bench to bedside.
19Current controversies in the surgical management of Crohn's disease.
20 Perianal Crohn's disease.
21 What is dysplasia?.
22 Colonoscopic surveillance - if and when?.
23Cancer: new colonoscopic techniques.
24 Molecular markers - a realistic hope?.
25 Adenomas versus dysplasia associated lesion or mass - recognition and management?.
V Special management problems.
26 Growth impairment in children.
27 Osteopenia.
28 Pregnancy.
29 Can prognosis of ulcerative colitis be predicted?.
Index
1 Global changes in incidence.
2 The role of genetics in inflammatory bowel disease.
3 Microbial sensing in the intestine by pattern recognition receptors.
4 The role of bacteria.
5 The appendix - how might it influence susceptibility to ulcerative.
colitis: the legend of Qebehsenuef.
II Diagnosis and assessment.
6 What are the controversies in histopathological diagnosis?.
7 The challenges of using capsule endoscopy in the diagnosis and management of inflammatory bowel disease.
8 Cross-sectional imaging of inflammatory bowel disease.
III Management of ulcerative colitis.
9 Mesalazine for maintenance therapy in ulcerative colitis - how much, how long?.
10 Refractory distal colitis.
11 Pharmabiotics and inflammatory bowel disease - on the verge of evidence-based medicine.
12 Current controversies in the surgical management of ulcerative colitis.
13 What are the causes and treatment of ileoanal pouch dysfunction?.
IV Management of Crohn's disease.
14 Is mesalazine useful in Crohn's disease?.
15 Steroids or nutrition?.
16 Do antibiotics have a role in Crohn's disease?.
17 The optimal use of infliximab in Crohn's disease.
18 Designer drugs: from bench to bedside.
19Current controversies in the surgical management of Crohn's disease.
20 Perianal Crohn's disease.
21 What is dysplasia?.
22 Colonoscopic surveillance - if and when?.
23Cancer: new colonoscopic techniques.
24 Molecular markers - a realistic hope?.
25 Adenomas versus dysplasia associated lesion or mass - recognition and management?.
V Special management problems.
26 Growth impairment in children.
27 Osteopenia.
28 Pregnancy.
29 Can prognosis of ulcerative colitis be predicted?.
Index
